Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 11081-11090 Newer>

The Motley Fool December 5, 2005 W.D. Crotty	Cashing In on Noven's Drug Patch An FDA advisory panel recommends approval of Noven's patch for attention deficit hyperactivity. For now, investors might be put off by the company's lofty valuation of 55 times trailing earnings.
The Motley Fool December 5, 2005 Nathan Parmelee	Portfolio Recovery on the Mend The market for bad debt may be showing signs of improvement. Investors love the news, pushing the stock up by more than 8% in Monday's midday trading.
The Motley Fool December 5, 2005 Alyce Lomax	Baby Talk at Coach Think Coach is too expensive for baby? It may seem silly at first, but the luxury retailer has been doing quite well as an investment.
The Motley Fool December 5, 2005 Richard Moore	Don't Give Up on Real Estate The commercial real estate market still looks good. Investors: CB Richard Ellis, Jones Lang LaSalle, Trammell Crow, are all worth taking a look at.
The Motley Fool December 5, 2005 Tim Beyers	Knight Ridder's Problem With Democracy The CEO laments shareholder rights. Is he for real? Knight Ridder keeps finding ways to make less and less money. Which is probably why it has proved to be a poor investment. What other recourse do shareholders have than to agitate for a sale?
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool December 5, 2005 Rich Smith	Another Thorn in Lions' Paw Lions Gate lowers its earnings estimate. If huge hits like DreamWorks' Shrek 2 and Pixar's The Incredibles are struggling on DVD, a smaller outfit like Lions Gate may be in even deeper trouble. Investors, take note.
The Motley Fool December 5, 2005 Rich Smith	Market's Knickers in a Twist Ceradyne is raising some cash. So what? When a company whose share price has roughly doubled over the past six months decides to convert some of that equity into cash that it can use as it wishes, this is at worst a non-event.
The Motley Fool December 5, 2005 W.D. Crotty	Rigel Pharmaceuticals Gets Stomped The biotech tumbles on poor phase 2 trial results for an allergy drug. Until another compound begins to offer glimmers of hope, this stock will probably offer little if any price appreciation.
The Motley Fool December 5, 2005 Jeremy MacNealy	Do I Smell Money? Accelerating sales and improving margins continue to drive Parlux Fragrances' stock higher.
<Older 11081-11090 Newer> Return to current articles.